27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Abbott Laboratories (NYSE:ABT) has scored clearance from the FDA for its latest 3D cardiac mapping platform, designed to help physicians target abnormal heart rhythms.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
- The EnSite X EP system threads a catheter into the heart to chart out the regions of the cardiac muscle where unsteady electric pulses can cause irregular heartbeats and then guides surgeons in treating those areas with ablation procedures.
- The device incorporates Abbott’s omnipolar technology, which allows the probe to accurately record 360 degrees of electrical activity in real-time, regardless of how the catheter is oriented within the heart’s chambers.
- According to the Company, the system can map 1 million points in the heart while allowing the user to employ both unipolar and bipolar measurement principles, enabling both wider viewing of the heart and pinpoint measuring for specific areas of concern.
- Price Action: ABT shares are down 1.21% at $134.06 during the market session on the last check Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.